SEC Form 10-Q filed by NovaBay Pharmaceuticals Inc.
$NBY
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because
EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed NovaBay's Chief Executive Officer and a director of the Company. Former Chief Executive Officer Justin Hall has assumed the newly created position of Vice President of Business Development. At NovaBay's Special Meeting on April 16, 2025, stockholders
Stockholders as of the March 18, 2025 record date will be entitled to vote Company engages financial advisor to explore strategic options should stockholders fail to approve the dissolution proposal NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it will hold a virtual Special Meeting on April 16, 2025, at which stockholders will vote on a proposal for the liquidation and dissolution of the Company under Delaware law, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Dissolution"). The Special Meeting was announced in a preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission ("SEC") on F
8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
10-Q - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
3 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because
EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed NovaBay's Chief Executive Officer and a director of the Company. Former Chief Executive Officer Justin Hall has assumed the newly created position of Vice President of Business Development. At NovaBay's Special Meeting on April 16, 2025, stockholders
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi
SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)